Semaglutide and NASH: what the approval means, and what comes next

How the July 2026 MHRA approval came about

The MASH indication did not arrive without substantial groundwork. Clinical trials examining semaglutide in people with non-alcoholic or metabolic-associated fatty liver disease had been running for several years, showing that the same GLP-1 receptor activity that reduces appetite and slows gastric emptying also has effects on liver inflammation and fibrosis markers. The MHRA's decision on 3 July 2026, confirmed via GOV.UK's official announcement, granted conditional marketing authorisation for Wegovy in adults with MASH and moderate-to-advanced liver fibrosis. The word "conditional" matters here: it signals that regulators judged the benefit-risk balance to be favourable based on available data, while requiring Novo Nordisk to generate further real-world evidence. That is not unusual for a first-in-class approval in a condition where no licensed treatment previously existed. It reflects scientific honesty rather than doubt.

MASH sits on a spectrum. Simple fatty liver (steatosis) can, in some people, progress to steatohepatitis (where inflammation accompanies fat accumulation) and in some cases to fibrosis or cirrhosis. The approved indication targets the more serious end: moderate-to-advanced fibrosis, where halting progression matters most. Whether a patient's liver disease sits within that definition is a clinical determination, not something a symptom checklist can resolve.

What the trial evidence actually showed in liver outcomes

The phase 3 data underpinning the MASH licence came from trials examining semaglutide's effects on liver histology, actual biopsy-confirmed changes in liver tissue rather than indirect markers alone. Results showed meaningful reductions in steatohepatitis activity and, in a proportion of participants, improvement in fibrosis stage. These are hard endpoints that had proved difficult to achieve in earlier drug programmes for MASH, which is part of why the approval drew attention from hepatologists internationally.

It is worth being specific about what the data did and did not show. Improvement was not universal; not every participant achieved a histological response. And because the condition involves a slow biological process, longer follow-up studies continue. The NHS medicines information for semaglutide will be updated as post-approval evidence accumulates, and the GOV.UK announcement notes the conditional nature of the authorisation. Citing the trial results accurately means acknowledging the range of outcomes rather than presenting a single figure as the whole story.

The weight-loss data for semaglutide (around 15% average body-weight reduction over 68 weeks in the STEP 1 trial) is separately established and is what supports the weight-management licence. The liver-disease indication is built on different, liver-specific endpoints. The two are related biologically, because reducing excess body fat reliably reduces liver fat load, but the licences are distinct.

MASH, MASH, and the language shift, why it matters on a practical level

You may have searched for NASH rather than MASH. Both refer to the same underlying condition; the terminology shifted across recent years as the medical field moved away from language centred on alcohol absence ("non-alcoholic") towards language that reflects the metabolic drivers of the disease. Most clinical documentation published before 2024 uses NASH; the MHRA approval and current NHS guidance use MASH. If your specialist has written NASH on any documentation, that is not a different diagnosis: the new approval still applies to the same patient population.

This matters practically because people researching their condition may find older patient information that references NASH without mentioning semaglutide as a licensed option, simply because that information predates July 2026. The regulatory landscape changed this summer, and the terminology can make it harder to find current information. If you are managing this condition and wondering how recent developments fit your treatment plan, your hepatologist or specialist is the right person to interpret the approval in the context of your specific fibrosis staging and comorbidities.

Semaglutide for weight management: a separate but related route for some people

Many people with MASH also carry excess weight, and the overlap between obesity and liver disease is well-documented. For adults whose primary concern is weight management rather than a formal MASH diagnosis, semaglutide as Wegovy continues to be licensed for weight loss in adults with a BMI of 30 or above, or from 27 where a weight-related health condition is present. That is a different route with different clinical criteria.

If you are exploring whether weight-management treatment with semaglutide might be appropriate, you can read about Wegovy in more detail, including eligibility and what the consultation involves. A broader look at weight-loss treatment options is also available if you want to compare what is currently licensed and dispensed. Thinking about cost alongside clinical suitability is reasonable; the context around Wegovy pricing in the UK may help you make sense of what private treatment involves. These are prescription-only medicines regardless of indication, and a prescriber needs to assess the full picture before anything is dispensed, including being aware of potential side effects such as skin reactions that some people experience on semaglutide.

If you have been living with MASH for some time, you may feel a mix of cautious relief and uncertainty about what this approval changes day-to-day. That response makes sense. A single regulatory decision does not automatically translate into access or a treatment plan; it opens a door that a specialist then decides whether to walk through with you. Our clinical team at nume can review whether weight-management treatment is appropriate for your situation, though the MASH liver indication itself sits within specialist hepatology services rather than a private weight-management pharmacy. If you have questions about the process, including how semaglutide 1 mg dosing fits into a treatment plan, our FAQs are a useful place to start.